國家衛生研究院 NHRI:Item 3990099045/10462
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 914401      Online Users : 1366
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10462


    Title: Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis
    Authors: Tseng, CH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: BACKGROUND: The association between metformin and colorectal cancer (CRC) has rarely been investigated in Asian populations. METHODS: This retrospective cohort study included patients with newly diagnosed type 2 diabetes during 1999-2005, recruited from Taiwan's National Health Insurance database. A total of 169,601 patients (original cohort: 153,270 ever-users and 16,331 never-users of metformin) and a subgroup of 1:1 propensity-score-matched pairs of 16,331 ever-users and 16,331 never-users (matched cohort) were followed up to 31 December 2011. Cox regression was constructed with the inverse probability of treatment-weighting, using propensity scores, and was used to estimate hazard ratios (HRs). RESULTS: In the original cohort, the incidence of CRC was 242.9 and 480.9 per 100,000 person-years, respectively, in ever- and never-users. The overall HR [0.50, 95% confidence interval (CI): 0.45-0.56] suggested a significantly lower risk in metformin users, while compared with never-users, the HR (95% CI) for the first (<27.1 months), second (27.1-58.1 months) and third (>58.1 months) tertiles of cumulative duration of metformin therapy was 0.86 (0.76-0.98), 0.51 (0.45-0.59) and 0.26 (0.23-0.30), respectively. Analyses in the matched cohort showed similar findings with an overall HR of 0.62 (0.53-0.74), and a tertile analysis HR of 1.02 (0.81-1.28), 0.70 (0.56-0.89) and 0.32 (0.23-0.43), respectively. Re-analyses using more stringent diagnoses of CRC and cumulative duration as a continuous variable have consistently supported a protective effect with metformin use. CONCLUSION: Metformin is associated with a lower frequency of CRC.
    Date: 2017-10
    Relation: Diabetes and Metabolism. 2017 Oct;43(5):438-445.
    Link to: http://dx.doi.org/10.1016/j.diabet.2017.03.004
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1262-3636&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000418394600006
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85018637845
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB28438547.pdf1492KbAdobe PDF175View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback